Last reviewed · How we verify

Control group(autologous ICBG) — Competitive Intelligence Brief

Control group(autologous ICBG) (Control group(autologous ICBG)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Orthopedic Surgery / Bone Regeneration.

marketed Orthopedic Surgery / Bone Regeneration Small molecule Live · refreshed every 30 min

Target snapshot

Control group(autologous ICBG) (Control group(autologous ICBG)) — The University of Texas Health Science Center, Houston. Autologous iliac crest bone graft (ICBG) provides structural support and biological factors to promote bone healing and regeneration at the graft site.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Control group(autologous ICBG) TARGET Control group(autologous ICBG) The University of Texas Health Science Center, Houston marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Control group(autologous ICBG) — Competitive Intelligence Brief. https://druglandscape.com/ci/control-group-autologous-icbg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: